Top insider buys and sells disclosed on Friday
Relmada Therapeutics (RLMD) executives bought shares at $4.10-$4.25. PVH (PVH) CEO bought $1M in stock. Clipper Realty (CLPR) director bought $388K in shares. Gloo (GLOO) chair bought 50,000 shares. Hagerty (HGTY) sold $122M in shares. Dell (DELL) saw $55M in sales by Silver Lake. Hinge Health (HNGE) CEO sold $22.3M in shares.
How this was made
The 30-second read
Why it matters
While some insiders are adding to positions, several major shareholders are divesting sizable stakes, creating mixed signals for traders.
Market read
The filings provide fresh data for traders monitoring insider sentiment, but the overall market impact is limited.
What to watch
Buy‑side actions (Relmada, PVH) may reflect strategic positioning not captured by price alone.
Background
The article aggregates recent Form 4 filings, highlighting notable insider purchases and sales for a set of U.S. listed companies.
Ticker impact
CEO and CFO of Relmada Therapeutics bought shares worth $1.67M over two days, indicating confidence in the micro‑cap biotech.
Potential modest upside of 5‑10% if buying continues.
Buyers are top executives; purchase size is notable relative to market cap.
PVH CEO purchased $1M of stock as the share price had fallen 5% over the week, suggesting belief in undervaluation.
Possible short‑term rally of 3‑5%.
CEO buying after a recent decline often signals confidence.
Director/10% owner bought $388k of Clipper Realty, adding to his stake amid a 5.6% weekly gain.
Limited upside, 2‑4% support level.
Purchase size modest relative to market cap.
Executive chair bought 50k shares ($166.9k) while the stock sits near a 67% drop from its 52‑week high.
Potential stabilization, 3‑6% bounce.
Small purchase relative to float; stock heavily depressed.
10% owner sold 10.6M shares for $122M, a large divestiture after the stock rose to $13.55.
Possible downside of 5‑8% on near‑term.
Sizeable sell by a major shareholder often signals concerns.
Silver Lake affiliates sold roughly $55M of Dell Class C shares across two filings, indicating possible valuation concerns.
Potential short‑term dip of 3‑6%.
Large sell by a 10% owner; stock near 52‑week high.
CEO and spouse sold $22.3M of Hinge Health shares under a 10b5‑1 plan as the stock nears its 52‑week high.
Possible pullback of 4‑7%.
Large sell amount; timing coincides with peak price.
Market effects
Insider activity across biotech, apparel, REIT, software, insurance, and tech may hint at sector‑wide confidence shifts.
Primarily U.S. equities; limited broader market effect.
Low global impact; isolated to individual stocks.
Counterpoint
Large insider sells (Dell, Hagerty, Hinge Health) could signal overvaluation despite recent price gains.
Key entities
- companyRelmada Therapeutics, Inc.
Biotech firm with recent insider buying.
- companyDell Technologies Inc.
Technology hardware maker with large insider sell.
